NSC001 not checked

NSC-Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor”In the company’s words, NCT06995573 on ClinicalTrials.gov
Tested for
Alzheimer Disease
Main trialPhase 1/2
“The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.”In the company’s words, NCT06995573 on ClinicalTrials.gov

Other drugs for Alzheimer Disease

All 90 drugs for Alzheimer Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 30 Jul 2026 A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NSC001

Following is part of Solo: you see every change to NSC001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in